Immunotherapy

• State of the art: Neoantigens, T-cell recognition and tumour rejection
• Translation: Clinical application of neoantigen-reactive T-cells
• Opportunities to reduce dosing frequency of checkpoint inhibitors
• Dosing reductions of checkpoint inhibitors in lung cancer
• Personalised cancer vaccines in ovarian cancer
• AI assisted-integrative view of the tumour microenvironment
• Genomics correlates of response to immunotherapy
• Computational biology of antigen processing and presentation: A key to personalised immunotherapy of cancer
• AI in radiomics
• Precision hematopoietic stem cell replacement therapy
• Novel biomarkers for oncolytic virotherapy: Using transcriptomics to understand newcastle disease virus
• Invited Discussant 129O and 1O
• Probody therapeutics: Protease-activated antibody prodrugs for the treatment of cancer
• Association of long non-coding RNA biomarkers with clinically immune subtype and prediction of immunotherapy in patients with cancer
• Locoregional delivery of immunotherapy
• ESMO Preceptorship on Advanced Non Resectable Hepatocellular Carcinoma, Biliary and Pancreatic Cancer Paris December 2019
• Neoadjuvant immunotherapy for melanoma
• Radiomics approach in relation to immunotherapy
• Consensus on MSI/MMR determination to select patients eligible for anti-PD1 therapies
• Immune therapeutics in gastroesophageal cancer
• Immune therapeutics in HCC
• Mechanisms of immunotherapy efficacy versus resistance
• A retrospective, observational study of telomerase peptide immunotherapy in heavily treated solid cancer patients
• Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study
• Predicting onset and continuity of patient-reported symptoms in cancer patients undergoing immune checkpoint inhibitor (ICI) therapies using machin...

• « Previous
• 1
• 2
• ...
• 97
• Next »